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Enteroviruses are RNA viruses within the Picornaviridae family. Enteroviruses derive their name from the
way they are typically transmitted via the intestinal tract. They commonly infect millions of people every
year and often do not cause severe disease in immunocompetent patients with few exceptions. Aseptic
meningitis is a classic manifestation and is usually self-limited, however, can lead to severe neurological
complications in an immunocompromised individual. It has been well-described that patients with
hypogammaglobulinemia are predisposed to developing chronic enteroviral meningoencephalitis [1].
This is the ﬁrst reported case of enteroviral meningoencephalitis in a patient being treated for psoriatic
arthritis with rituximab. Here we describe a 46-year-old female who presented with altered mental
status, fever, and myalgia. Polymerase chain reaction (PCR) of her cerebrospinal ﬂuid (CSF) conﬁrmed the
presence of enterovirus. In the immunocompromised patient with encephalopathy, it is important to
consider an enteroviral infection. This case adds to the present body of knowledge about enteroviral
infections in immunocompromised hosts.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Rituximab is a chimeric anti-CD20 monoclonal antibody that
induces a long-lasting B-cell depletion. It is presently FDAapproved for the treatment of non-Hodgkin’s lymphoma, chronic
lymphocytic leukemia, rheumatoid arthritis, granulomatosis with
polyangitis, microscopic polyangitis, and most recently pemphigus
vulgaris [2]. It has also been successfully used as a second-line
agent in the treatment of psoriatic arthritis [3]. Typically, the drug
has a respectable safety proﬁle. There is a Black Box Warning for
rituximab for a potentially fatal ﬁrst-time infusion reaction, severe
mucocutaneous reaction, hepatitis B virus reactivation, and
progressive multifocal leukoencephalopathy. Enteroviral meningoencephalitis is a lesser known but clinically signiﬁcant
complication of rituximab that has been recognized the recent
years.
Enteroviruses remain the most common cause of viral
meningitis in the United States with encephalitis recognized as
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a potential complication. Among immunocompetent individuals,
children are affected more frequently than adults. Typical
meningitis presentation in adults can include fever, headache,
stiff neck, vesicular lesions, and lymphocytic pleocytosis on CSF.
Rapid viral detection is imperative in establishing a proper
diagnosis that can ultimately improve patient outcome and avoid
unnecessary antibacterial usage and testing.
There have been several cases of enteroviral meningoencephalitis described in patients on rituximab since the ﬁrst reported case
in 2003 [4–14] (Table 1). All of these patients were receiving
rituximab in the setting of hematologic diseases. We report a novel
case of enteroviral meningoencephalitis in a patient on prolonged
rituximab therapy for psoriatic arthritis.
Case presentation
A 46-year-old African American female presented to an outside
hospital in late November 2017 due to altered mentation and ﬂu-like
symptoms. Her past medical history was signiﬁcant for bipolar
disorder, 1 seizure episode at age 17, and psoriatic arthritis treated
with rituximab infusions since 2014. Her last known rituximab
infusion was July 2017. Prior to seeking medical care, the patient tried
multiple doses of Theraﬂu (acetaminophen, dextromethorphan, and

https://doi.org/10.1016/j.idcr.2019.e00558
2214-2509/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Review of rituximab-associated enteroviral meningoencephalitis cases in the literature.
Age & Sex

Indication
for
Rituximab

Time since last
Rituximab

Symptoms

CSF Findings

Treatment & Outcome

Quartier
et al. [4]

10M

AITP

18 months post ﬁrst
cycle, 11 months post
second cycle

-Lymphocytosis
-Increased protein
-EV RNA

-High dose IVIG & Pleconaril
-Resolution with residual learning
disabilities & behavioral problems

Quartier
et al. [4]

55M

FL

6 months

-Lymphocytosis
-Increased protein
-EV RNA

-High dose IVIG & Pleconaril
-Resolution with residual deafness & mild
pyramidal syndrome

GarzoCaldas
et al. [5]

66M

WM

1 month

-Altered cognitive
function
-Aphasia
-Sensorimotor
deafness
-Mild fever
-Extrapyramidal
syndrome
-Fever
-Headaches
-Diffuse paresthesia
-Trouble
concentrating
-Sensorimotor
deafness
-Diplopia
-Pyramidal
syndrome
-Ataxia
-Drowsiness
-Fever
-Encephalopathy

-IVIG
-Transient improvement, died 7 months later
from pneumonia

Ganjoo et al.
[6]

42M

DLBCL

16 months
(NR)

-Lymphocytosis
-Increased protein
-Normal glucose
-PCR negative
(Enterovirus detection on right
temporal lobe biopsy)
-Lymphocytosis
-Increased protein
-Normal glucose
-EV RNA

Shaheen
et al. [7]

5M

BL

During treatment

-Lymphocytosis
-Increased protein
-EV RNA

-IVIG
-Resolution with residual impaired
cognition, aphasia, and movement disorders

Grisarui et al. 6 patients
[8]
described:
65
33
34
67
62
62

FL
FL
DLBCL
MCL
FL
FL

Various

-Lymphocytosis
-Increased protein
-EV RNA
-Decreased glucose

-IVIG, death
-IVIG, Resolution
-No speciﬁc treatment, Resolution
-IVIG, Resolution with residual hearing loss
-IVIG, death
-IVIG, Resolution

Kassab et al.
[9]

66F

FL

2 months, on
maintenance therapy

-Lymphocytosis
-Increased protein
-Normal to mildly increased
glucose on 3 CSF samples
-EV RNA

-No speciﬁc treatment
-Died 32 days after admission

Schilthuizen
et al. [10]

64F

MZL

During maintenance
therapy

-Lymphocytosis
-Increased protein
-EV RNA

-IVIG
-Resolution

Padate et al.
[11]

75M

DLBCL

7 months

-Lymphocytosis
-Increased protein
-CSF initially negative to

-Broad-spectrum antibiotics, acyclovir,
ganciclovir, IVIG
-Clinical improvement followed by

-Progressive
neurologic
debilitating
dysfunction
-Dysarthria
-Nystagmus
-Psychomotor
retardation
-Fever
-Seizures
-Impaired
consciousness
-Globally increased
tone
-Brisk reﬂexes
-Positive Babinski
reﬂex
-Fever
-Weight loss
-Cognitive
impairment
-Hypoalbuminemia
-Headache
-Cough
-Reduced DLCO
-Muscle weakness
-Rash
-Tinnitus
-Axonal
polyneuropathy
-Hearing loss
-Gait disturbances
-Fever
-Asthenia
-Psychomotor
retardation
-Aphasia
-Facial paralysis
-Spastic movements
-Impaired
consciousness
-Fever
-Nausea/Vomiting
-Weight loss/
Fatigue
-Gastroenteritis
-Septicemia
-Low GCS
-Fever

-Died before planned administration of IVIG
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Table 1 (Continued)
Age & Sex

Indication
for
Rituximab

Time since last
Rituximab

Servais et al.
[12]

61F

DLBCL

4 months

KianiAlikhan
et al. [13]

53M

DLBCL

During treatment

Palacios et al. 28F
[14]

Evans
Syndrome
& ITP

12 years

Our Patient

Psoriatic
arthritis

4 months

46F

Symptoms

CSF Findings

Treatment & Outcome

-Confusion
-Agitation,
disinhibition
-Confusion
-Ataxia
-Cerebellar
syndrome

enterovirus, transformed to
positive for EV RNA

neurological deterioration and death due to
intercurrent infection

-Lymphocytosis
-Increased protein
-Normal glucose
-Initially negative, positive for
EV RNA 2 months later
-Lymphocytosis
-Initially negative, positive for
EV RNA 1 month later

-IVIG
-Resolution with neurological improvement

-Lymphocytosis
-Increased protein
-Initially persistently negative,
EV RNA found on brain biopsy
and CSF per CDC
-Lymphocytosis
-Increased protein
-Normal glucose
-EV RNA

-IVIG
-Died following left MCA ischemic stroke
while in hospice

-Fever
-Ataxia
-Difﬁculty
concentrating
-Dysarthria
-Cerebellar signs
-Positive Babinski
reﬂex
-Sensorineural
hearing loss
-Fever
-Neurocognitive
decline
-Fever
-Myalgias
-Cough
-Obtundation
-Generalized
stiffness
-Decreased visual
acuity

-IVIG
Neurological deterioration and death

-IVIG
-Residual deﬁcits including cortical
blindness, hallucinations, discoordination,
intermittent altered mentation

AITP, autoimmune thrombocytopenia; FL, follicular lymphoma; WM, Waldenstrom’s macroglobulinemia; DLBCL, diffuse large B cell lymphoma; BL, Burkitt lymphoma; MCL,
mantle cell lymphoma; MZL, marginal zone lymphoma; GCS, Glasgow Coma Scale; EV, enteroviral; ITP, idiopathic thrombocytopenic purpura; CDC, Centers for Disease
Control and Prevention.

phenylephrine) because she attributed her symptomatology to
inﬂuenza.
She complained of a subjective tactile fever, myalgias, and
cough. Initial physical exam revealed the patient to be normotensive and afebrile, but she did have nuchal rigidity, was obtunded
and showed generalized stiffness with her arms ﬂexed and legs
extended. Initial emergency department workup included a CT
scan of the brain without contrast that showed no mass effect or
hemorrhages and normal gray-white differentiation. Complete
blood count (CBC) on admission showed a leukocytosis of 18,000/
uL with an absolute neutrophil count of 15,600/uL. C-reactive
protein (CRP) was elevated at 156.8 mg/L. A lumbar puncture
showed a high WBC count of 161/uL with 70% lymphocytes, 25%
PMNs, 98 mg/dL protein, and 55 mg/dL glucose. The patient was
placed on isolation precautions and empirically started on
ceftriaxone, vancomycin, and acyclovir. A CSF BioFire Meningitis/
Encephalitis Panel revealed the presence of enterovirus. As a result,
empiric antimicrobials were discontinued. On subsequent hospital
days, the patient continued to have generalized stiffness, was
unable to follow commands, and remained nonverbal. She
experienced recurrent febrile episodes as well as multiple
witnessed generalized tonic-clonic seizures. An EEG showed
abnormal bihemispheric slowing suggestive of nonspeciﬁc diffuse
encephalopathy. Attempted brain MRI on hospital day 5 was not
successful. The patient did not improve, had recurrent febrile
episodes with leukocytosis, and frequent seizures. A brain MRI
under sedation revealed restricted diffusion in the bilateral cortical
and subcortical regions of the parietal and posterior temporal
lobes, splenium of the corpus callosum, and bilaterally in the
posterior thalamus (Fig. 1). These ﬁndings raised concern for
posterior reversible encephalopathy syndrome (PRES) at the
outside facility.

The patient was transferred to our tertiary care facility. On
arrival, the patient remained altered with disorientation to person,
place, and time. She showed left gaze preference and was unable to
follow simple one-step commands. Her reﬂexes, muscle tone, and
sensorium were normal. CRP was elevated at 64.2 mg/L. Her liver
function studies and pancreatic studies were unremarkable.
Intracranial and extracranial CT angiography showed no abnormalities. Brain MRI showed restricted diffusion in the splenium of
the corpus callosum. Left greater than right restricted diffusion in
the temporoparietal cortex was present. Subtle leptomeningeal
enhancement on the left was also observed. Folate, vitamin B12,
vitamin B1, and TSH levels were all within the normal reference
ranges.
The patient improved clinically and was able to follow one-step
commands. However, she had intermittent episodes of agitation
requiring four-point restraints. She was placed on olanzapine as
needed with haloperidol for breakthrough agitation. Follow-up
brain MRI two weeks later showed stable FLAIR and T2 signal
abnormalities within the splenium of the corpus callosum and
thalami with no residual hypointensity on ADC map images,
indicating no persisting restricted diffusion in these locations.
Previous temporoparietal diffusion hyperintensities also had
returned to normal and no new areas of signal abnormalities
were identiﬁed (Fig. 2). At this point, the patient was awaiting
placement in a skilled nursing facility. Her mentation and
orientation continued to improve. Her episodes of aggression
and agitation lessened.
A month after admission, the patient complained of decreased
visual acuity. She was found to have decreased bilateral blink-tothreat reﬂexes with left-gaze preference. However, she was able to
distinguish colors and track around the room. As a result, a repeat
brain MRI was done on January 10, 2018. New cortical-restricted
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Fig. 1. MRI Brain: Fig. 1A Axial DWI. Restricted diffusion in posterior temporal, parietal, and bilateral occipital lobe cortex. Restricted diffusion in splenium of corpus callosum
and bilateral posterior thalami. Fig. 1B Axial DWI. Restricted diffusion in parietal lobe cortex. Fig. 1C Axial T1. Leptomeningeal enhancement.

Fig. 2. MRI Brain: Fig. 2A Axial T2. T2 hyperintensity persists in splenium of corpus callosum. Fig. 2B Axial DWI. Residual hyperintense signal in splenium of corpus callosum is
present, in the absence of ADC map hypointensity. This combination of ﬁndings indicates “T2 shine through” effect, which follows the acute phase of cytotoxic edema after
approximately 2 weeks. The distinction is important as this pattern reﬂects chronic injury as opposed to new or ongoing injury. Diffusion weighted hyperintensity associated
with the prior restricted diffusion in the cortex has subsided, suggesting “pseudonormalization” after ischemic/infectious insult.

diffusion was present in the bilateral parietal and occipital lobes.
Stable abnormal diffusion abnormality within the splenium of the
corpus callosum and thalami remained (Fig. 3). These ﬁndings
were concerning for Creutzfeldt-Jakob Disease but a 14-3-3 protein
analysis was found to be within the normal reference range and
real-time quaking-induced conversion failed to detect abnormal
prion proteins.
Repeat CSF PCR for enterovirus was negative as well as a swab of
the oropharynx. Cerebrospinal ﬂuid testing for California (La
Crosse) encephalitis, John Cunningham virus, Mycobacterium
tuberculosis, Eastern equine encephalitis virus, Cryptococcus neoformans, VZV, HSV-1, HSV-2, CMV, VDRL for neurosyphilis, and
angiotensin converting enzyme for neurosarcoidosis all proved to
be negative. An India ink stain was performed and proved to be
negative. Serum and plasma testing for hepatitis B virus, hepatitis C
virus, HIV-1, HIV-2, John Cunningham virus, Borrelia burgdorferi,
Borrelia mayonii, Borrelia Garinii, and Borrelia afzelii were all
negative. The prior hospital had tested a CSF sample for West Nile

virus and Streptococcus pneumoniae antigen, both of which were
negative. Blood and CSF cultures showed no growth for bacteria or
fungi. The patient did have a positive QuantiFERON-TB Gold test.
However, a follow-up chest X-ray was negative, AFB sputum
culture ultimately showed no growth for 42 days, and sputum PCR
for Mycobaterium tuberculosis was negative.
A serum Epilepsy Autoimmune Evaluation (Mayo Clinic
Laboratories) failed to reveal any of the 19 autoantibodies tested.
A serum NeoCerebellar Degeneration Paraneoplastic Proﬁle with
Recombx (Quest Diagnostics) was unremarkable for any autoantibodies indicative of cerebellar degeneration. CSF and serum
paraneoplastic autoantibody evaluations were negative. The
patient’s IgM, IgG, and IgA levels were all within the normal
reference ranges. She ultimately received a ﬁve-day course of
400 mg/kg/day IVIG. Although the patient was not at baseline, she
was discharged in an improved clinical condition with decreased
visual acuity. She was instructed to follow-up as an outpatient with
neurology, psychiatry, and infectious disease.
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Fig. 3. MRI Brain Axial FLAIR: Hyperintense signal in cortex of bilateral parietal
lobes indicates cortical injury, and corresponds to the original location of signal
abnormality in cortex.

Discussion
The presence of enterovirus in the patient’s CSF was established
with the use of a CSF BioFire Meningitis/Encephalitis Panel. This
panel is a molecular test used to assess the presence of 14 bacterial,
viral, and fungal pathogens. It has an overall sensitivity of 94.2%
and speciﬁcity of 99.9% [15]. The patient later had a repeat CSF PCR
analysis that was negative for the presence of enterovirus.
However, there are documented cases in the literature in which
a CSF PCR for enterovirus was negative yet positive conﬁrmation
was obtained through a brain biopsy [5,14]. Our patient did not
undergo a brain biopsy.
The cortical and subcortical parietal and posterior temporal
lobe diffusion abnormalities observed on brain MRI (Fig. 1) prior to
transfer to our facility raised concern for posterior reversible
encephalopathy syndrome (PRES). PRES typically has an acute
presentation and commonly manifests as seizures, visual disturbances, headache, and altered mental status [17]. Hypertension
is seen in over 70% of patients, and renal injury is frequently
present [18]. There are cases in the literature of PRES occurring
within hours to days after the infusion of rituximab with resolution
of symptoms in 1–2 days and no lasting residual deﬁcits [19]. Our
patient persistently had a blood urea nitrogen level under 12 mg/
dL and a creatinine under 0.90 mg/dL. Her last rituximab infusion
was 4 months prior to presentation which is inconsistent with
prior cases of PRES after rituximab. In addition, she continues to
have neurological deﬁcits including decreased visual acuity. Given
the aforementioned, PRES is an unlikely etiology.
Determining the etiology of encephalitis can be diagnostically
challenging and even careful examination of a brain biopsy
specimen can fall short [16]. Prior reported cases of enteroviral
meningoencephalitis in association with rituximab have demonstrated thalamus and basal ganglia involvement on MRI, which is
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Fig. 4. MRI Brain Axial T2: regional bilateral enlargement of the posterior bodies
and trigones of lateral ventricles indicates deep white matter volume loss. Cortical
loss and thinning correspond to locations where prior studies had shown FLAIR and
T2 hyperintense signal, restricted diffusion on DWI, and leptomeningeal enhancement.

similar to what we have observed in our patient [6,7,9].
Autoimmune encephalitis was considered highly unlikely as all
neurologic antibody studies were negative. Although this does not
completely exclude autoimmune encephalitis as a possible
etiology, it is interesting to note that rituximab is recommended
as part of the treatment for autoimmune encephalitis, even in the
absence of an identiﬁed antibody [20].
Previously, the administration of high-dose IVIG and pleconaril,
an antipicornaviral agent, were the mainstay of treatment for
enteroviral meningoencephalitis [1,4,10]. However, there is very
little evidence in the present body of medical literature to support
this. In addition, pleconaril is no longer available in the United
States. Previous reports of patients with rituximab related
enteroviral meningoencephalitis describe lasting neurologic residual deﬁcits and behavioral problems [4,7,8]. This is consistent
with our patient’s current state. She has cortical blindness,
episodes of altered mental status with agitation and visual
hallucinations, aphasia requiring speech therapy, altered balance
and discoordination requiring physical therapy. Her most recent
MRI done 10 months after discharge shows ex vacuo dilatation of
the occipital horns of the lateral ventricles and bilateral occipital
lobe encephalomalacia (Fig. 4). Chronic meningoencephalitis is a
rare and potentially fatal complication of a typically nonthreatening pathogen. It should be an important clinical consideration in an
immunocompromised patient on prolonged rituximab therapy.
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